Recent news on Mylotarg

Gemtuzumab Ozogamicin Boosts Effects of Arsenic Trioxide in High ...  -  May 22, 2007
DG NewsTherefore, Dr. Sekeres and colleagues conducted a trial in which they evaluated a combination arsenic trioxide and gemtuzumab ozogamicin (Mylotarg®) in

Lonza plans to commercially produce emerging class of drugs  -  May 10, 2007
DrugResearcher.com,Currently, there is only one antibody-drug conjugate on the market, which is Mylotarg (gemtuzumab ozogamicin) manufactured by Wyeth.

T cell antibodies to treat diabetes  -  Apr 10, 2007
LabTechnologist.com,If, in the future, they decided to resurrect this research, Dr MacKenzie pointed to Wyeth's Mylotarg (gemtuzumab ozogamicin) product as an example of how it

Wyeth Up on Completing Japan Unit Buyout  -  Apr 3, 2007
Forbes,Wyeth KK sells products such as Enbrel for the treatment of rheumatoid arthritis and psoriasis in Japan, as well as Mylotarg, a bone marrow cancer treatment

Wyeth Completes Purchase of Wyeth KK Japan  -  Apr 5, 2007
Drug Newswire (press release),Enbrel and Mylotarg(R), biological products launched in Japan in 2005, are helping to drive WKK's growth. The history of WKK began in 1953 with Lederle

Wyeth buys out Takeda's 20% stake in Japanese unit  -  Apr 4, 2007
Pharma Times (subscription),It was noted that Mylotarg (gemtuzumab ozogamicin), a humanised anti-CD33 monoclonal antibody indicated for the treatment of acute myeloid leukaemia,

• Donald Goodman, 84, bequeathed millions to medical institutions  -  Mar 7, 2007
Cleveland Plain Dealer,When he got his first diagnosis of the terminal blood cancer in 2000, he acted as a guinea pig for Mylotarg, a new FDA-approved drug.

New drug brings hope for Brett  -  Feb 8, 2007
Advertiser 24,Boat-builder Brett Dingwall, aged 56, of Drop Lane, Bricket Wood, has emerged from a course of treatment with the drug Mylotarg with his leukaemia in

PDL BioPharma Announces Fourth Quarter and Full Year 2006 ...  -  Feb 21, 2007
Yahoo! News (press release)Synagis is a registered trademark of MedImmune, Inc. Mylotarg is a registered trademark of Wyeth. Tysabri is a registered trademark of Elan Pharmaceuticals,

PDL BioPharma Announces Fourth Quarter and Full Year 2006 ...  -  Feb 21, 2007
Earthtimes.orgInc.; Synagis(R) antibody product from MedImmune, Inc.; Tysabri(R) antibody product from Elan Pharmaceuticals, Inc.; and Mylotarg(R) antibody product

Mylotarg® May Decrease Relapse Rate in Patients with Newly ...  -  Jan 16, 2007
Cancer Consultants (press release),Researchers affiliated with the MRC AML 15 trial have reported that the addition of Mylotarg (gemtuzumab ozogamicin) to one of three different induction

Mylotarg® and Vidaza® Effective for Elderly Patients with AML or MDS  -  Jan 5, 2007
Cancer Consultants (press release),Researchers from Loyola University have reported that the combination of Mylotarg® (gemtuzumab ozogamicin) and Vidaza® (azacitidine) produces a high rate of

ASH: Mylotarg Boosts AML Disease-Free Survival  -  Dec 12, 2006
MedPage Today,..."It's the first randomized trial of Mylotarg, and it does indeed seem to have an advantage in reducing the relapse risk without increasing toxicity."

Increased Use of Wyeth's Mylotarg and Launches of New Drugs Will ...  Oct 16, 2006
...for pharmaceutical and healthcare issues, finds that the launch of novel, premium-priced drugs and the progression of Wyeth's Mylotarg (gemtuzumab ozogamicin ... -PR Newswire (press release), Analysis: Shake-up in the leukemia market  Oct 16, 2006
16 (UPI) -- An analyst report projects Pfizer's acute myeloid leukemia treatment Idamycin will lose its top spot to Wyeth's Mylotarg and Genzyme/Bioenvision's ... -United Press International PDL BioPharma Announces Third Quarter 2006 Financial Results  Nov 2, 2006
Inc. and Mylotarg(R) from Wyeth. ... Synagis is a registered trademark of MedImmune, Inc. Mylotarg is a registered trademark of Wyeth. Tysabri ... -Earthtimes.org -- Mitchel L. Zoler  Sep 18, 2006
He helped design the studies that made the drug gemtuzumab ozogamicin (Mylotarg) available to patients with acute myeloid leukemia. ... -Philadelphia Jewish Voice

ASH: Mylotarg Boosts AML Disease-Free Survival  -  12 Dec 2006
MedPage Today,..."It's the first randomized trial of Mylotarg, and it does indeed seem to have an advantage in reducing the relapse risk without increasing toxicity."

Cancer - The New Frontier: Doomed in the womb - cancer that starts ...  -  Nov 22, 2006
New Zealand Herald,Several New Zealand patients are also involved in clinical trials for Mylotarg, which works on the same principle as Herceptin. It binds to a protein on the

United Kingdom: Science Feature - Nanotechnology  Aug 10, 2006
...already been exploited in medicine to powerful effect: the breast cancer drug Herceptin is a nanoscale antibody, and the anti-leukaemia drug Mylotarg is based ... -Mondaq News Alerts (subcription)

PDL BioPharma Announces Second Quarter 2006 Financial Results  Aug 3, 2006
...and Mylotarg® from Wyeth. ... Synagis is a registered US trademark of MedImmune, Inc. Mylotarg is a registered US trademark of Wyeth. PDL BIOPHARMA, INC. ... -Yahoo! News

ODAC Committee to Meet Nov. 8 On Accelerated Approval Commitments  Jun 30, 2006
...s Ontak® (denileukin diftitox), SkyePharma’s DepoCyt® (liposomal cytarabine), Pfizer’s Celebrex® (celecoxib), Wyeth’s Mylotarg® (gemituzumab) and ... -Cancer Consultants



Acceleron Pharma Appoints Matthew L. Sherman, MD as Chief Medical ...  16 May 2006
...development of 12 development projects for both small molecule and biologic therapeutics, including the submission and approval of Mylotarg(R) (gemtuzumab ... - Genetic Engineering News

PDL BioPharma Announces First Quarter 2006 Financial Results  May 2, 2006
...antibody humanization patents: Avastin(TM), Herceptin(R), Xolair(R) and Raptiva(R) from Genentech, Inc.; Synagis(R) from MedImmune, Inc.; Mylotarg(R) from ... - MSN Money

PDL BioPharma Announces First Quarter 2006 Financial Results  May 2, 2006
...antibody humanization patents: Avastin(TM), Herceptin®, Xolair® and Raptiva® from Genentech, Inc.; Synagis® from MedImmune, Inc.; Mylotarg® from Wyeth and ... - Yahoo! News





Wyeth increases equity in Takeda joint venture  11 Apr 2006
According to Wyeth, growth of Wyeth KK (WKK) is being driven by the arthritis drug Enbrel and the anticancer drug Mylotarg, biological products launched in ... - Pharmaceutical Business Review

Wyeth boosts stake in Japanese venture to 80%  Apr 7, 2006
Wyeth said the two products that were launched in Japan in 2005 -- arthritis drug Enbrel and cancer treatment Mylotarg -- are helping to drive Wyeth KK's growth ... - MarketWatch

Wyeth Acquires an Additional Stake in Wyeth KK Japan  Apr 7, 2006
...confidential. Enbrel and Mylotarg, biological products launched in Japan in 2005, are helping to drive WKK's rapid growth. "The ... - PR Newswire

Wyeth Purchases Additional 10% Stake In Wyeth KK, Japan - Update  Apr 7, 2006
The company noted that two biological products, Enbrel and Mylotarg, which was launched in Japan in 2005, are helping to drive Wyeth KK's rapid growth. ... - Trading Markets



PDL BioPharma Announces Fourth Quarter and Full Year 2005 ...  Feb 27, 2006
...antibody humanization patents: Avastin(TM), Herceptin(R), Xolair(R) and Raptiva(R) from Genentech, Inc.; Synagis(R) from MedImmune, Inc.; Mylotarg(R) from ... - PR Newswire,

The nano state is here  Feb 24, 2006
The first nanomedicine of this sort was the anti-leukaemia drug Mylotarg. Many more are either on the market or completing clinical trials. ... - Times Online,

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional